Finoriq research workspace
AEON Biopharma, Inc. (AEON) News
AEON Biopharma, Inc. develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical. Review AEON recent headlines, source links, and company news on Finoriq.
Company Snapshot
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
- Company
- AEON Biopharma, Inc. (AEON)
- Ticker
- AEON
- Market Cap
- $12.9M
- Latest Price
- $0.291
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.